Related Experiment Video
Updated: Aug 16, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
Antihypertensive drug use and the risk of prostate cancer (Canada)
Linda Perron1, Isabelle Bairati, François Harel
1Centre de recherche en cancérologie de l'Université Laval, Canada.
Purpose:
To verify if exposure to antihypertensive drugs was associated to prostate cancer (PC) risk.
Methods:
We conducted a matched case-control study using record linkage between two population-based databases. We defined exposure as a binary variable and in terms of timing and cumulative duration of use. We controlled for detection bias and Aspirin use.
Results:
Among the 2221 cases and 11,105 controls, use of any antihypertensive agent was associated with an adjusted relative risk of PC of 0.98 (CI, 0.88-1.08). Of the different classes of antihypertensives, only beta-blockers (BBs) were associated with a reduction in PC risk (OR = 0.86, CI = 0.77-0.96). In those who cumulated < 1, 1-4, and > or = 4 years of BB use, the risk was 0.89 (0.75-1.05), 0.91 (0.75-1.09), and 0.82 (0.69-0.96), respectively. Also, subjects with > or = 4 years of alpha-blocker (ABs) use had a non-significant 25% reduction in PC risk.
Conclusions:
Our results suggest that BBs and long-term use of ABs may prevent PC whereas calcium channel blockers or angiotensin-converting enzyme inhibitors do not influence PC risk.
Related Concept Videos
Antihypertensive Drugs: Direct Renin Inhibitors
Antihypertensive Drugs: Vasodilators
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Disorders of the Male Reproductive System
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Hypertension IV: Drug Therapy and Lifestyle Modifications

